Wednesday, February 2, 2011

Lancet Oncology: Urorad and IMRT

A very blunt interview with Anthony Zeitman is published in Lancet Oncology, blasting the Urorad business model.

[News] US urology clinics overprescribe prostate radiotherapy: "The US Government Accountability Office is investigating allegations that urologists are reaping hundreds of millions of dollars by overprescribing intensity-modulated radiotherapy (IMRT) for prostate cancer. Since 2002, Medicare, the federal health insurance programme for elderly patients, has paid generously for IMRT—up to US$40 000 per patient."

No comments: